David Simmons. PPD via YouTube

What are bio­phar­ma com­pa­nies hir­ing CROs for these days? PPD spells it out in bid for $100M IPO

More than eight years af­ter PPD was tak­en pri­vate in a $3.9 bil­lion deal, the 35-years-old con­tract re­search or­ga­ni­za­tion is brac­ing for the pub­lic mar­ket again with a $100 mil­lion ask.

Hav­ing served all of the top 50 bio­phar­ma com­pa­nies in the world by R&D spend­ing and over 300 biotech fledg­lings, PPD’s fil­ings high­light­ed the en­trenched role CROs play in an in­dus­try chas­ing an ever dwin­dling re­turn on in­vest­ment by push­ing for faster time­lines and tack­ling pay­er re­sis­tance to pricey ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.